Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORCEPT-E 1/35 28 vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy,Oral contraceptive
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
DHIVY is not a recognized drug. No dosing information available.
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and CYP2C9.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone: >97% bound to albumin and SHBG; ethinyl estradiol: >97% bound to albumin. Ethinyl estradiol also binds to SHBG with lower affinity.
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Norethindrone: approximately 3.5 L/kg; ethinyl estradiol: approximately 2.5 L/kg. These values reflect extensive tissue distribution and binding to tissues such as breast, uterus, and adipose.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Norethindrone ~64% (first-pass metabolism); ethinyl estradiol ~40-50% (extensive first-pass metabolism). Factors such as food and individual differences may affect bioavailability.
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in acute renal disease or marked renal impairment.
Not applicable.
Contraindicated in severe hepatic disease or liver tumors (benign or malignant). Use with caution in mild to moderate hepatic impairment; dose adjustment generally not required but monitor for adverse effects.
Not applicable.
Not indicated for use before menarche. After menarche, use same adult dosing schedule.
Not applicable.
No specific dose adjustment; use with caution due to increased risk of thromboembolic disorders and cardiovascular events in women over 35 who smoke.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, stroke, myocardial infarction) from combination oral contraceptives, especially in women over 35 and heavy smokers (>15 cigarettes/day).
No FDA black box warnings.
Thrombotic disorders (DVT, PE, stroke, MI),Hepatic tumors,Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular lesions (retinal thrombosis),Hereditary angioedema,Chloasma,Depression
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Thrombophlebitis or thromboembolic disorders,History of DVT/PE,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
No significant food interactions. Grapefruit juice does not affect ethinyl estradiol. Avoid St. John's wort (herbal supplement) as it reduces contraceptive efficacy.
No data available for DHIVY.
First trimester: Increased risk of neural tube defects, cardiovascular malformations, and limb reduction defects if inadvertently exposed to the progestin component (norethindrone) at high doses. Second and third trimesters: No evidence of teratogenicity from estrogen-progestin combinations; however, androgenic effects (pseudohermaphroditism in female fetuses) have been reported with high doses of progestins. Overall, combination oral contraceptives are contraindicated in pregnancy.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk (M/P ratio for ethinyl estradiol approximately 0.75; for norethindrone, about 0.66). Use may reduce milk production and quality, especially in early postpartum. Avoid in nursing mothers unless essential; alternative contraception recommended.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Contraindicated during pregnancy. No dose adjustments recommended as drug should be stopped immediately upon pregnancy diagnosis.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
NORCEPT-E 1/35 28 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norethindrone 1 mg. It is indicated for contraception and may be used off-label for menstrual disorders. Pearl: Counsel patients that missed pills increase pregnancy risk; refer to prescribing information for missed dose instructions. Monitor for thromboembolic events, especially in smokers over 35. Drug interactions: rifampin, certain anticonvulsants (e.g., phenytoin, carbamazepine), and St. John's wort reduce efficacy. Breakthrough bleeding common in first 3 cycles; if persistent, evaluate for non-compliance or alternative causes.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one pill daily at the same time, preferably after an evening meal or at bedtime to minimize nausea.,Missed pill? Take as soon as remembered; if >48 hours, use backup contraception (condoms) for 7 days and consult the package insert.,Report immediately: severe leg pain/chest pain/sudden shortness of breath (signs of blood clot), severe headache, vision changes, or jaundice.,Smoking increases risk of serious cardiovascular side effects; avoid smoking especially if over 35.,May decrease efficacy with certain antibiotics (non-rifampin) – use backup contraception during antibiotic course and for 7 days after.,Do not take if pregnant, breastfeeding, or have history of blood clots, stroke, breast cancer, liver disease, or migraine with aura.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORCEPT-E 1/35 28 vs DHIVY, answered by our medical review team.
NORCEPT-E 1/35 28 is a Combined Oral Contraceptive that works by Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORCEPT-E 1/35 28 and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORCEPT-E 1/35 28 is: 1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORCEPT-E 1/35 28 and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORCEPT-E 1/35 28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular malformations, and limb reduction defects if inadvertently exposed to the progestin component (norethindrone). DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.